Earnings Report /
Thailand

Chularat Hospital PCL: Huge beat! Strong YoY growth outlook for 1Q22

  • Far above our estimate and the consensus

  • CHG posted a record profit of Bt1,813m for 4Q21

  • CHG announced a DPS of Bt0.17 for 2H21

Bualuang Securities
28 February 2022

The market can be expected to bid up the stock substantially, following CHG’s spectacular 4Q21 result and street 2022 earnings forecast upgrade flows. It currently trades at a 2022 PER only 21.6x, 35% below its long-term average of 33.4x. Our BUY call stands to a YE22 DCF-derived target price of Bt4.60 (7.3% WACC and a 2.0% terminal growth rate).

Far above our estimate and the consensus

CHG posted a record profit of Bt1,813m for 4Q21, up by 615% YoY and 16% QoQ. The result was 155% above our estimate and 113% ahead of the consensus (revenue was 47% higher and GM 18% fatter than we had assumed). CHG announced a DPS of Bt0.17 for 2H21 (in line our assumption, but above the street), a 4.9% simple yield (XD May 5, payment May 20).